What Is the Chemical Formula for Potassium Phosphate. Repeated Dosing Normalize the calcium before administering Potassium Phosphates INJECTION [, Potassium Phosphates INJECTION is only for administration to a patient with a serum potassium concentration less than 4 mEq/dL[, Do not infuse with calcium-containing intravenous fluids [see, The rate of administration may be dependent on the patient and the specific institution policy [. Limitations of Use Clinical Considerations Monitor serum phosphorus, potassium, calcium and magnesium concentrations during treatment [see Dosage and Administration (2.2, 2.4)]. Inform patients, caregivers or home healthcare providers of the following risks of Potassium Phosphates INJECTION: Distributed by: Potassium phosphate. Potassium Phosphates INJECTION is indicated as a source of phosphorus for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or contraindicated. Potassium Phosphates INJECTION is indicated as a source of phosphorus for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or contraindicated. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Potassium Phosphates INJECTION must be diluted and administered in intravenous fluids or used as an admixture in parenteral nutrition. Want to re-post this article? Visually inspect the solution for particulate matter and discoloration before and after dilution and prior to administration. It is supplied as a 15 mL partial fill single-dose glass vial. The recommended and maximum daily dosage in parenteral nutrition is shown in Table 2. Potassium Phosphates INJECTION, USP: phosphorus 45 mmol/15 mL (3 mmol/mL) and potassium 71 mEq/15 mL (4.7 mEq/mL) as a clear and colorless solution supplied in a 15 mL single-dose glass vial (NDC 46287-024-15) in a ten count carton (NDC 46287-024-10). Potassium Phosphates INJECTION is contraindicated in patients with hyperphosphatemia and/or hypercalcemia [see Contraindications (4)]. In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 to < 60 mL/min/1.73 m2), start at the low end of the dosage range and monitor serum potassium, phosphorus, calcium, and magnesium concentrations [see Dosage and Administration (2.2, 2.4)]. (H 2 O) x (x = 0, 3, 7, 9). Hyperkalemia b In patients with moderate renal impairment (eGFR ≥30 mL/min/1.73 m2 to <60 mL/min/1.73 m2), start at the low end of the dosage range. The chemical formulas for two nutritional and medicinal forms of potassium phosphate are KH2PO4 for the monobasic ionic salt (monopotassium phosphate), and K2HPO4 for the dibasic ionic salt (dipotassium phosphate). Potassium Phosphates INJECTION, USP, is a phosphorus replacement product containing phosphorus 45 mmol/15 mL (3 mmol/mL) and potassium 71 mEq/15 mL (4.7 mEq/mL). The final parenteral nutrition solution is for intravenous infusion into a peripheral or central vein. Chemical Safety: Laboratory Chemical Safety Summary (LCSS) Datasheet. In addition, inappropriate intravenous administration of undiluted or insufficiently diluted Potassium Phosphates as a rapid “IV push” has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death. Safety has not been established for parenteral nutrition in adults weighing less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due to the risk of aluminum toxicity [see Warnings and Precautions (5.5), Use in Specific Population (8.4)].